新闻中心-》公司新闻列表页 – SmartNuclide

SmartNuclide raises nearly 100 million yuan in series C funding round04/08/2024

Suzhou SmartNuclide Biopharmaceutical Company (SmartNuc […]

SmartNuclide’s new drug approved for treatment of differentiated thyroid cancer in China04/23/2024

Suzhou, April 11, 2024 – Suzhou Smartnuclide biopharmac […]

Innovative Radiopharmaceutical Company SmartNuclide Closes Series Pre-A Financing08/08/2018

SUZHOU INDUSTRIAL PARK, March 8, 2018 – Suzhou SmartNuc […]

SmartNuclide’s SNA001 Receives NMPA’s First Investigational New Drug Approval for Recombinant Human TSH10/08/2018

SUZHOU INDUSTRIAL PARK, Oct. 18, 2018 – Suzhou SmartNuc […]

SmartNuclide Biopharma Announces First Patient Treated in Phase 1/2 Clinical Trial of SNA001 for Well-Differentiated Thyroid Cancer02/12/2019

SUZHOU INDUSTRIAL PARK, Feb. 13, 2019 – Suzhou SmartNuc […]

The kick-off meeting of phase III clinical trial of rhTSH Drug SNA001 developed by SmartNuclide was held in Suzhou02/12/2020

The kick-off meeting of phase III clinical trial of rhT […]

SmartNuclide announced the completion of nearly RMB 100 million round B financing04/29/2020

SUZHOU INDUSTRIAL PARK, April, 2020 – Suzhou SmartNucli […]

Smart Nuclide Raises 100 million yuan in a series C funding round05/31/2022

Suzhou, China, April 13, 2022 – Suzhou Smart Nucl […]